在查看本专题的其他语言版本时,您可能会发现内容结构上的一些差异,但仍然是最新的循证指导。

Last reviewed: 15 一月 2026
Last updated: 04 七月 2025

Summary

Definition

History and exam

Key diagnostic factors

  • decreased libido
  • loss of spontaneous morning erections
  • erectile dysfunction
  • normocytic anaemia
  • gynaecomastia
  • subfertility
  • micropenis
  • small testes
  • bifid or hypoplastic scrotum
  • cryptorchidismespecially if bilateral
  • segmental dysproportion
  • bitemporal hemianopia
  • low trauma fractures
  • loss of height
  • anosmia
Full details

Other diagnostic factors

  • decreased energy and fatigue
  • absent or incomplete puberty
  • scrotal hypoplasiahypopigmentationand absent rugae
  • decreased muscle mass and strength
  • loss of axillary and pubic hair
  • lack of facial hair
  • poor concentration and memory
  • depressed or labile mood
  • sleep disturbance
  • hot flushes and sweats
  • tall stature
  • fine wrinkling of facial skin
Full details

Risk factors

  • genetic anomaly
  • type 2 diabetes mellitus
  • use of alkylating agentsopioidsor glucocorticoids
  • use of exogenous sex hormones and GnRH analogues
  • hyperprolactinaemia
  • parasellar tumour or apoplexy of pituitary macroadenoma
  • testicular damage
  • infection
  • varicocele
Full details

Diagnostic investigations

1st investigations to order

  • serum total testosterone
Full details

Investigations to consider

  • serum sex hormone-binding globulin (SHBG)
  • calculated free testosterone
  • serum LH/FSH
  • semen analysis
  • FBC
  • serum prolactin
  • serum transferrin saturation and ferritin
  • MRI pituitary
  • genetic testing
  • dual-energy x-ray absorptiometry (DEXA or DXA)
Full details

Treatment algorithm

ONGOING

non-gonadal illness

not desiring fertility currently: primary hypogonadism

not desiring fertility currently: secondary hypogonadism

desiring fertility currently: primary hypogonadism

desiring fertility currently: secondary hypogonadism

Contributors

Authors

Richard QuintonMD FRCP(Edin)

Consultant Endocrinologist

Northern Region Gender Dysphoria Service

Tyne & Wear NHS Foundation Trust

Newcastle upon Tyne

UK

Honorary Reader in Reproductive Endocrinology

Department of MetabolismDigestion and Reproduction

Imperial College London

UK

Disclosures

RQ has received speaker fees and an advisory board fee from Besins Healthcare UKspeaker fees from Androlabsand was on an advisory board for Roche Diagnostics. RQ is an author of several references cited in this topic.

Channa N. JayasenaPhD FRCP FRCPath

Consultant and Reader in Reproductive Endocrinology/Andrology

Department of Investigative Medicine

Hammersmith Hospital

Imperial College London

London

UK

Disclosures

CNJ has an investigator-led research grant from LogixX Pharma Ltd. CNJ is supported by a National Institute for Health Research (NIHR) Post-Doctoral Fellowship. CNJ is an author of several references cited in this topic.

Acknowledgements

Dr Richard Quinton and Dr Channa N. Jayasena would like to gratefully acknowledge Dr Charles WelliverDr T. Hugh JonesDr Milena Braga-Basariaand Dr Shehzad Basariaprevious contributors to this topic.

Disclosures

CW has worked as a consultant for Coloplastand as an investigator for Auxilium PharmaceuticalsMereo BioPharmaPROCEPT BioRoboticsand Repros; and he is a paid reviewer at Oakstone Publishing and BMJ Best Practice. CW also has a family member who is an employee at Bristol-Myers Squibb. THJ and SB are authors of references cited in this topic. MB declared that she had no competing interests.

Peer reviewers

Randal J. UrbanMD

Professor

Department of Internal Medicine

University of Texas Medical Branch

Galveston

TX

Disclosures

RJU declares that he has no competing interests.

Niki KaravitakiMBBSMScPhD

Consultant Endocrinologist

Oxford Centre for DiabetesEndocrinology and Metabolism

Churchill Hospital

Oxford

UK

Disclosures

NK declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Mulhall JPTrost LWBrannigan REet al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018 Aug;200(2):423-32.Full text  Abstract

Jayasena CNAnderson RALlahana Set al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022 Feb;96(2):200-19.Full text  Abstract

Matsumoto AM. Diagnosis and evaluation of hypogonadism. Endocrinol Metab Clin North Am. 2022 Mar;51(1):47-62. Abstract

Bhasin SBrito JPCunningham GRet al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-44.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Differentials

    • Klinefelter syndrome
    • Pituitary macroadenoma
    • Prolactinoma
    More Differentials
  • Guidelines

    • Guidelines for testosterone replacement therapy in male hypogonadism
    • Fertility problems: assessment and treatment
    More Guidelines
  • Patient information

    Erection problems

    Fertility problems: some reasons

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer